AmpliPhi BioSciences Corporation 800 East Leigh Street Richmond, VA 23219 Press Release AmpliPhi Provides Corporate Update and Reports First Quarter 2015 Financial Results San Diego and Richmond, VA, USA, Ljubljana, Slov

Corporate Update and Reports First Quarter 2015 Financial Results

San Diego and Richmond,

VA, USA, Ljubljana, Slovenia, and Sydney, Australia, May 19 2015 - AmpliPhi BioSciences Corporation (OTCQB: APHB),

a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided

a corporate update and announced financial results for the first quarter ended March 31, 2015.

on the progress made to date in 2015, Jeremy Curnock Cook, Chairman of AmpliPhi said, "Over the past few months, AmpliPhi

has made a number of significant advancements in reinforcing our foundation, through new appointments to the executive leadership

team, continued positive progress with our planned clinical trial programs and securing critical intellectual property that will

protect our platform technologies. AmpliPhi is well-positioned to move forward with plans to further establish itself as the leading

phage company in the world, and I am encouraged by the exciting prospects for the year ahead."

2015 Financial Results:

result of the $13 million financing, the Company has significantly improved it overall liquidity and balance sheet strength in

preparation for both executing on its R&D activities and preparing for an anticipated listing on a major national stock exchange.

a significantly improved balance sheet, AmpliPhi remains in a favorable position to continue our development of novel bacteriophage-based

therapies to address the growing global epidemic of treatment-resistant bacteria," said M. Scott Salka, CEO of AmpliPhi.

"Furthermore, through a combination of a strong product pipeline, established intellectual property protection and existing

collaborations with world-class research institutions, I am confident that AmpliPhi will continue this trend of positive momentum

to help meet our near and long-term goals."

The Company is planning to

provide a mid-year corporate update via live conference call and webcast during its upcoming Annual Shareholder's Meeting

on June 30, 2015 in Washington, D.C.

AmpliPhi BioSciences Corporation

(OTCQB: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial

therapeutics. The Company's product development programs target infections that are often resistant to existing antibiotic treatments.

AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE: XON), the U.S. Army, The

Royal Brompton Clinic in London, UK and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies.

For more information, visit www.ampliphibio.com.

Bacteriophage are naturally

occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves

in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms

are a major line of defence for bacteria, contributing to antibiotic resistance.

Bacteriophage are able to

penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.

press release about AmpliPhi's manufacturing capabilities and ability to manufacture pure, reproducible, high quality, cost

effective human preparations, the potential use of bacteriophages to treat bacterial infections, including infections in biofilms

and infections that do not respond to antibiotics, and the development of bacteriophage-based therapies are forward looking statements

subject to risks and uncertainties, including without limitation the risk that the Company will not be able to successfully manufacture

sufficient quantities of products to conduct clinical trials or commercialize products in a timely manner or at all, that AmpliPhi

may not commence clinical trials or complete IND- enabling studies as expected, that the clinical trials will not be successful,

that further development of the Company's products will require extensive and expensive nonclinical and clinical testing, may

not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign

regulatory agency. For a further description of the risks and uncertainties that could cause actual results to differ from those

expressed in these forward-looking statements, as well as risks relating to AmpliPhi's business in general, see AmpliPhi's Annual

Report on Form 10-K for the fiscal year ended December 31, 2014, as amended, filed with the Securities and Exchange Commission

(SEC) on April 15, 2015.